Drug intelligence / Profile preview

ABL206

Development stage: Preclinical
Lead developer: NEOK Bio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABL206 is a preclinical antibody-drug conjugate (ADC) developed by ABL Bio. It is designed to target a specific molecule designated as 'Target A3,' which is associated with the Transforming Growth Factor Beta (TGFB) signaling pathway. By conjugating a target-specific antibody to a cytotoxic payload, ABL206 aims to selectively deliver cell-killing agents to tumor cells or components of the tumor microenvironment that express the A3 target. This approach is intended to inhibit tumor growth and potentially counteract TGFB-mediated immunosuppression and fibrosis within the tumor microenvironment.

Other names: ABL206-ABL Bio-Target A3 (TGFB)-ADC

Targets

ROR1 (Receptor tyrosine kinase-like orphan receptor 1)B7-H3TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on ABL206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABL206.

Explore the full profile